Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups Journal Article

   

Authors:	Hsiehchen, D.; Espinoza, M.; Valero, C.; Ahn, C.; Morris, L. G. T.
Article Title:	Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups
Abstract:	The FDA approval of immune checkpoint inhibitors for cancers with tumor mutation burden (TMB) of at least 10 mut/Mb is postulated to reduce healthcare disparities by broadly expanding treatment eligibility. In a cohort of 39,400 patients with available genomic and race data, black and Asian patients were less likely to have TMB-high cancers in multiple types of malignancies based on the currently approved cut-off. Decreasing TMB thresholds preferentially increased the eligibility of minority patients for immune checkpoint inhibitors while retaining predictive value of treatment benefit in a cohort of immune checkpoint inhibitor treated patients. This study highlights differing distributions of TMB-high cancers between racial groups and provides guidance in developing more rational eligibility criteria for immune checkpoint inhibitors.
Keywords:	immunotherapy; blockade; tumor biomarkers; pembrolizumab; fda approval
Journal Title:	Journal for ImmunoTherapy of Cancer
Volume:	9
Issue:	11
ISSN:	2051-1426
Publisher:	Biomed Central Ltd
Date Published:	2021-11-01
Start Page:	e003683
Language:	English
ACCESSION:	WOS:000720981900006
DOI:	10.1136/jitc-2021-003683
PROVIDER:	wos
PMCID:	PMC8603286
PUBMED:	34795008
Notes:	Article -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/190763